Consequently, in DLBCL and other diseases, rational use of specific BH3-mimetics mandates robust identification of predictive biomarkers and this is now an area of intense research.300–303 Co-expression of alternative anti-apoptotic proteins, protein interactions and accessibility and phosphorylation status of BCL2 all likely contribute to venetoclax resistance in cases of high BCL2 expression. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.